Dr. Martin on the Need for Head-to-Head Comparisons of BTK Inhibitors in MCL

Peter Martin, MD, chief, the Lymphoma Program, Meyer Cancer Center, associate professor of medicine, Weill Cornell Medicine, discusses the need for head-to-head comparison of BTK inhibitors in mantle cell lymphoma (MCL).

​The BTK inhibitors ibrutinib (Imbruvica), acalabrutinib (Calquence), and zanubrutinib (Brukinsa) ​are approved for the treatment of patients with MCL ​who have received at least 1 prior line of therapy, says Martin.

However, there is little evidence to suggest if one agent should be selected over another based on efficacy or safety, Martin explains.

As such, a ​randomized phase 3 ​trial comparing these agents head-to-head is warranted, Martin concludes.